Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)

被引：0

作者：

Parnis, F. ^{[1
]}

Tombal, B. ^{[2
]}

Hussain, M. ^{[3
]}

Saad, F. ^{[4
]}

Fizazi, K. ^{[5
]}

Sternberg, C. N. ^{[6
]}

Crawford, E. D. ^{[7
]}

Kopyltsov, E. ^{[8
]}

Kalebasty, A. Rezazadeh ^{[9
]}

Alekseev, B. Y. ^{[10
]}

Montesa Pino, A. ^{[11
]}

Ye, D. ^{[12
]}

Melo Cruz, F. J. S. ^{[13
]}

Tammela, T. ^{[14
]}

Suzuki, H. ^{[15
]}

Joensuu, H. ^{[16
]}

Thiele, S. ^{[17
]}

Li, R. ^{[18
]}

Kuss, I. ^{[19
]}

Smith, M. ^{[20
]}

机构：

[1] Ashford Canc Ctr Res, Dept Med Oncol, Kurralta Pk, SA, Australia

[2] Catholic Univ Louvain, Div Urol IREC, Clin Univ St Luc, Brussels, Belgium

[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Sch Med, Chicago, IL 60611 USA

[4] Ctr Hosp Univ Montreal CRCHUM, Dept Urol, Montreal, PQ, Canada

[5] Inst Gustave Roussy, Dept Canc Med, Villejuif, France

[6] Weill Cornell Med, Div Hematol & Oncol, Belfer Res Bldg, New York, NY USA

[7] Univ Calif San Diego, Dept Urol, Sch Med, San Diego, CA USA

[8] OMSK Reg Oncol Ctr, Clin Oncol, Omsk, Russia

[9] Univ Calif Irvine, UCI Hlth, Hematol Oncol & Med Dept, Orange, FL USA

[10] PA Hertsen Moscow Oncol Res Inst, Oncol, Moscow, Russia

[11] Hosp Reg Univ Malaga Carlos Haya, Oncol, Malaga, Spain

[12] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[13] Janssen Cilag Farmaceut Ltd, Dept Med Oncol, Sao Paulo, Brazil

[14] Tampere Univ Hosp, Dept Med Oncol, Tampere, Finland

[15] Toho Univ, Med Ctr, Sakura Hosp, Dept Urol, Sakura, Japan

[16] HUCH Helsinki Univ Cent Hosp, Dept Oncol, Helsinki, Finland

[17] Bayer AG, Clin Dev Oncol Dept, Berlin, Germany

[18] Bayer Healthcare Pharmaceut Inc, Clin Stat US SBU Oncol, Whippany, NJ 07981 USA

[19] Bayer AG, Clin Dev SBU Oncol, Berlin, Germany

[20] Massachusetts Gen Hosp, Oncol, Boston, MA 02114 USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.10.210

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

173TIP

引用

页码：S1501 / S1502

页数：2

共 50 条

[21] Darolutamide (DARO) in combination with androgendeprivation therapy (ADT) and docetaxel (DOC) in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) in the phase III ARASENS study
Wang, S.
Fu, C.
Li, Y.
Xing, J.
Zhou, L.
Yang, Y.
Wang, H.
Smith, M. R.
Tombal, B.
Hussain, M.
Niu, Y.
Cai, L.
Liu, Q.
Littleton, N.
Li, R.
Ye, D.
ANNALS OF ONCOLOGY, 2023, 34 : S1572 - S1572
[22] Metastatic hormone-sensitive prostate cancer
Gravis, Gwenaelle
Salem, Naji
Walz, Jochen
BULLETIN DU CANCER, 2015, 102 (01) : 57 - 64
[23] Feasibility of cotargeting cell cycle and androgen signaling in metastatic hormone-sensitive prostate cancer (mHSPC).
Palmbos, Phillip Lee
Tomlins, Scott A.
Agarwal, Neeraj
Twardowski, Przemyslaw
Morgans, Alicia Katherine
Kelly, William Kevin
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[24] Patient-reported outcomes in metastatic hormone-sensitive prostate cancer (mHSPC): Results from the China ARCHES trial
Ye, D.
Chang, Y.
Li, Y.
Zeng, G.
Guo, H.
Hu, Z.
Zhang, X.
He, D.
He, Z.
Zhang, D.
Lu, X.
Kadeerbai, H.
Liu, Y.
Zhou, F.
ANNALS OF ONCOLOGY, 2024, 35
[25] Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis
Uemura, Motohide
Kikukawa, Hiroaki
Hashimoto, Yasuhiro
Uemura, Hiroji
Mizokami, Atsushi
Kato, Masashi
Matsushima, Hisashi
Kosaka, Takeo
Nakamura, Motonobu
Fukasawa, Satoshi
Smith, Matthew R.
Tombal, Bertrand
Hussain, Maha
Saad, Fred
Fizazi, Karim
Sternberg, Cora N.
Crawford, E. David
Kakiuchi, Haruka
Akiyama, Masanao
Li, Rui
Kuss, Iris
Joensuu, Heikki
Suzuki, Hiroyoshi
CANCER MEDICINE, 2024, 13 (21):
[26] ARASENS: making sense out of first-line metastatic hormone-sensitive prostate cancer treatment
Aragon-Ching, Jeanny B.
ASIAN JOURNAL OF ANDROLOGY, 2023, 25 (01) : 1 - 4
[27] Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS study
Smith, Matthew R.
Hussain, Maha
Saad, Fred
Fizazi, Karim
Sternberg, Cora N.
Crawford, David
Manarite, Jan
Muslin, David
Farrington, Thomas
Tombal, Bertrand
FUTURE ONCOLOGY, 2022, 18 (21) : 2585 - 2597
[28] Erstlinientherapie beim metastasierten hormonsensitiven Prostatakarzinom (mHSPC)First-line treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
H. Rexer
S. Feyerabend
M. Graefen
Forum, 2023, 38 (3) : 238 - 239
[29] Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
Kenrick Ng
Shievon Smith
Jonathan Shamash
Oncology and Therapy, 2020, 8 : 209 - 230
[30] Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
Ng, Kenrick
Smith, Shievon
Shamash, Jonathan
ONCOLOGY AND THERAPY, 2020, 8 (02) : 209 - 230

← 1 2 3 4 5 →